Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lentiviral Gene Therapy for CGD
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.
Official title: Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2025-07-01
Completion Date
2029-12-31
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
Infusion of lentiviral TYF-CGD-modified autologous stem cells
Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China